Diagnosis Code Z85.46
Information for Medical Professionals
The following edits are applicable to this code:
Diagnoses for males only Diagnoses for males only
Diagnoses for males only.
Unacceptable principal diagnosis Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual’s health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.
Diagnostic Related Groups
The diagnosis code Z85.46 is grouped in the following Diagnostic Related Group(s) (MS-DRG V34.0)
- 826 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURE WITH MCC
- 827 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURE WITH CC
- 828 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURE WITHOUT CC/MCC
- 829 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER PROCEDURE WITH CC/MCC
- 830 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER PROCEDURE WITHOUT CC/MCC
Convert to ICD-9 General Equivalence Map
The ICD-10 and ICD-9 GEMs are used to facilitate linking between the diagnosis codes in ICD-9-CM and the new ICD-10-CM code set. The GEMs are the raw material from which providers, health information vendors and payers can derive specific applied mappings to meet their needs.
- V10.46 - Hx-prostatic malignancy
Present on Admission (POA) Present on Admission
The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement.
The code Z85.46 is exempt from POA reporting.
- History of malignant neoplasm of prostate
Information for Patients
The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American.
Symptoms of prostate cancer may include
- Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
- Low back pain
- Pain with ejaculation
To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy.
Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments.
NIH: National Cancer Institute
- Cryotherapy for prostate cancer (Medical Encyclopedia)
- Digital rectal exam (Medical Encyclopedia)
- Gleason grading system (Medical Encyclopedia)
- Hormone therapy for prostate cancer (Medical Encyclopedia)
- Pelvic (between the hips) radiation - discharge (Medical Encyclopedia)
- Prostate brachytherapy (Medical Encyclopedia)
- Prostate cancer (Medical Encyclopedia)
- Prostate cancer - treatment (Medical Encyclopedia)
- Prostate cancer staging (Medical Encyclopedia)
- Understanding Chemotherapy - NIH - Easy-to-Read (National Cancer Institute)
- Understanding your prostate cancer risk (Medical Encyclopedia)
- What to Know about Brachytherapy (A Type of Internal Radiation Therapy) - NIH - Easy-to-Read (National Cancer Institute)
- What to Know about External Beam Radiation Therapy - NIH - Easy-to-Read (National Cancer Institute)